Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Vasculitis
Do you offer biosimilar tocilizumab as an alternative to subcutaneous or infusion brand-name tocilizumab when treating GCA?
Related Questions
How would you manage a patient with Takayasu arteritis controlled on TNFi who develops erythema nodosum that is only partially responsive to NSAIDs?
Would you consider tocilizumab for treatment of GCA in patients with underlying CLL (not requiring therapy)?
How long do you continue rituximab in patients with ANCA associated vasculitis who have achieved remission?
How would you interpret the presence of both high titer anti-PR3 and anti-MPO antibodies in a pANCA positive patient with evidence of small vessel vasculitis?
How do you approach the management of patients with moderate to high pre-test probabilty of GCA who are found to have negative findings on temporal artery biopsy?
What is your experience of using rituximab for GPA with renal involvement following a recent myocardial infarction?
Are you aware of drug induced-ANCA vasculitis associated with new wt loss medications (ex tirzepatide or semaglutide)?
How would you approach management of a patient with classic GCA symptoms, elevated ESR and improvement with steroids, but negative temporal artery biopsy and CTA imaging without evidence of vasculitis?
Should patients starting cyclophosphamide be screened routinely for latent tuberculosis (TB)?
How would you approach management of nodular scleritis in the setting of suspected GCA?
